BBOT to Participate in Upcoming September Investor Healthcare Conferences

GlobeNewswire

Aug 20

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.

Details of the company’s participation are as follows:

Cantor Global Healthcare Conference
- Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York

Morgan Stanley Global Healthcare Conference
- Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York

Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Uneek Mehra, Chief Financial Officer
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560103964"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560103964\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560103964?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560103964","market":"us","top_or_hot":-1,"title":"BBOT to Participate in Upcoming September Investor Healthcare Conferences","media":"GlobeNewswire","content":"<html><body><p>SOUTH SAN FRANCISCO, Calif., Aug.  20, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BBOT\">BridgeBio Oncology Therapeutics, Inc</a>. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.</p> <p><strong>Details of the company’s participation are as follows:</strong></p> <ul type=\"disc\"><li><strong>Cantor Global Healthcare Conference</strong> <ul type=\"disc\"><li>Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York</li></ul> </li></ul> <ul type=\"disc\"><li><strong><a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> Global Healthcare Conference</strong> <ul type=\"disc\"><li>Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York</li></ul> </li></ul> <p>Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event.</p> <p><strong>About BBOT</strong><br/>BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit <strong>www.bbotx.com</strong> and follow us on <strong>LinkedIn</strong>.</p> <p><strong>BBOT Contacts:</strong></p> <p><strong>Investor Contact:</strong><br/>Uneek Mehra, Chief Financial Officer<br/>BBOT<br/><strong>Investors@BBOTx.com</strong> <br/></p> <p><strong>Media Contact:</strong><br/>Jake Robison<br/>Inizio Evoke Comms<br/><strong>Jake.robison@inizioevoke.com</strong></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NDUxYzdkZTItYjRjYy00ZDQ3LWE5NWQtM2E5MTVhYzJjOTc5LTEzMTQwNDctMjAyNS0wOC0yMC1lbg==/tiny/TheRas-Inc-d-b-a-BridgeBio-Onc.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBOT to Participate in Upcoming September Investor Healthcare Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBOT to Participate in Upcoming September Investor Healthcare Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-08-20 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>SOUTH SAN FRANCISCO, Calif., Aug.  20, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BBOT\">BridgeBio Oncology Therapeutics, Inc</a>. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.</p> <p><strong>Details of the company’s participation are as follows:</strong></p> <ul type=\"disc\"><li><strong>Cantor Global Healthcare Conference</strong> <ul type=\"disc\"><li>Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York</li></ul> </li></ul> <ul type=\"disc\"><li><strong><a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> Global Healthcare Conference</strong> <ul type=\"disc\"><li>Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York</li></ul> </li></ul> <p>Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event.</p> <p><strong>About BBOT</strong><br/>BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit <strong>www.bbotx.com</strong> and follow us on <strong>LinkedIn</strong>.</p> <p><strong>BBOT Contacts:</strong></p> <p><strong>Investor Contact:</strong><br/>Uneek Mehra, Chief Financial Officer<br/>BBOT<br/><strong>Investors@BBOTx.com</strong> <br/></p> <p><strong>Media Contact:</strong><br/>Jake Robison<br/>Inizio Evoke Comms<br/><strong>Jake.robison@inizioevoke.com</strong></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NDUxYzdkZTItYjRjYy00ZDQ3LWE5NWQtM2E5MTVhYzJjOTc5LTEzMTQwNDctMjAyNS0wOC0yMC1lbg==/tiny/TheRas-Inc-d-b-a-BridgeBio-Onc.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0158827781.USD","symbol_name":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/08/20/3136340/0/en/BBOT-to-Participate-in-Upcoming-September-Investor-Healthcare-Conferences.html","article_id":"2560103964","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560103964","pubTimestamp":1755691200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"SOUTH SAN FRANCISCO, Calif., Aug.  20, 2025  (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4581":"高盛持仓","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4585":"ETF&股票定投概念","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4534":"瑞士信贷持仓","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1548497426.USD":"安联环球人工智能AT Acc","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4127":"投资银行业与经纪业","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BBOT":"BridgeBio Oncology Therapeutics, Inc","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","HCSG":"Healthcare Svcs Group Inc","BK4516":"特朗普概念","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4504":"桥水持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0971096721.USD":"富达环球金融服务 A","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4137":"综合支持服务","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC"},"translate_title":"BBOT将参加即将于9月举行的投资者医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBOT":1,"HCSG":1},"content_text":"SOUTH SAN FRANCISCO, Calif., Aug.  20, 2025  (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September. Details of the company’s participation are as follows: Cantor Global Healthcare Conference Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York  Morgan Stanley Global Healthcare Conference Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York  Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event. About BBOTBBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn. BBOT Contacts: Investor Contact:Uneek Mehra, Chief Financial OfficerBBOTInvestors@BBOTx.com  Media Contact:Jake RobisonInizio Evoke CommsJake.robison@inizioevoke.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}